Loading patent…
OwnerJennifer Richardson, John Monahaninventors
Estimating the term…
Methods for identifying patients having or at risk of developing prostate cancer (including hormone refractory or androgen independent prostate cancer) and patients having or at risk of developing a cancer arising from metastasis if a prostate cancer to another tissue, e.g., liver and lymph node, by measuring the expression or activity of alpha-methylacyl-CoA racemase are described. The invention also provides: methods of screening for compounds that can be used to treat prostate cancer (including hormone refractory or androgen independent prostate cancer) or metastases of prostate cancer by screening for compounds that modulate the expression or activity of the alpha-methylacyl-CoA racemase polypeptides or nucleic acids; a process for modulating (i.e., reducing) alpha-methylacyl-CoA racemase polypeptide or nucleic acid expression or activity, e.g., using the screened compounds; and methods for selecting patients for therapy with a compound that reduces the activity or expression of alpha-methylacyl-CoA racemase as well as methods for determining whether such a therapy should be continued in a patient.
A method for determining whether an individual is at risk for prostate cancer, comprising:
A method for determining whether an individual is at risk for prostate cancer, comprising:
A method for determining whether a prostate cancer patient is at risk for metastatic prostate cancer to the liver, comprising:
A method for determining whether a prostate cancer patient is at risk for metastastic prostate cancer to the liver, comprising:
A method for determining whether a prostate cancer patient is at risk for metastatic prostate cancer to the lymph nodes, comprising:
A method for determining whether a prostate cancer patient is at risk for metastatic prostate cancer to the lymph nodes, comprising:
A method for selecting an individual for therapy with a compound which decreases alpha-methylacyl-CoA racemase expression, the method comprising:
A method for selecting an individual for therapy with a compound which decreases alpha-methylacyl-CoA racemase expression, the method comprising:
A method for selecting an individual for therapy with a compound which decreases alpha-methylacyl-CoA racemase expression, the method comprising:
A method for selecting an individual for therapy with a compound which decreases alpha-methylacyl-CoA racemase expression, the method comprising:
A method for identifying candidate therapeutic agents for the treatment of prostate cancer, the method comprising:
A method for identifying candidate therapeutic agents for the treatment of prostate cancer, the method comprising:
A method for determining whether a therapeutic treatment should be continued, the method comprising:
A method for determining whether a therapeutic treatment should be continued, the method comprising:
A method for treating prostate cancer comprising administering a compound which increases the expression or activity of alpha-methylacyl-CoA racemase.
A method for identifying candidate therapeutic agents for the treatment of prostate cancer, the method comprising:
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:10.
An isolated nucleic acid molecule comprising a sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11;
An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11;
Dependencies are inferred from the claim text.